Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
Recruiting
N/A
Interventional Study
Thromboembolic Venous Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 3,400 (estimated)
- Sponsor
- University Hospital, Brest · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease
* 50 and under or any age if active cancer
* Affiliated to social security
* Accepting to participate in the study.
Exclusion Criteria:
* Inabil…
Contacts